SUPPLEMENTARY APPENDIX

Online Supplementary Design and Methods
Cell cultures
Human erythroleukemic (K562) and murine erythroleukemia (MEL) cell lines were grown in suspension in RPMI 1640 (Lonza, Treviglio, Italy) supplemented with 10% fetal bovine serum (Clontech, Saint Germain en Laye, France), 100 μg/mL streptomycin, 100 U/mL penicillin and 2 mM L-glutamine (Sigma, Milan, Italy). Cells were incubated with 0.1 mM desferrioxamine (DFO) for 18 h for western blot analysis or with 1 mM DFO for 48 h for real-time quantitative polymerase chain reaction and apoptosis analysis. CD34
+ bone marrow cells were separated by two cycles of positive selection using the MiniMacs system (Miltenyi Biotech, Bergish Gladbach, Germany), according to the manufacturer's instructions, on mononuclear cells isolated by density gradient centrifugation from the bone marrow of healthy donors. Informed consent was obtained from the subjects and the study followed the guidelines of the research ethical committee of the IRCCS Policlinico San Matteo in Pavia. FtMt-transduced and control CD34 + cells (see below) were seeded onto plates at a density of 1¥10 5 cells/mL in Iscove's medium (Sigma) supplemented with 1% penicillin and streptomycin, 1% L-glutamine, 15% BIT9500 serum substitute, 10 ng/mL interleukin-3, 10 ng/mL interleukin-6 and 25 ng/mL stem cell factor (Tebu-Bio, Magenta, Italy) and cultured for 21 days. Recombinant human erythropoietin (Santa Cruz Biotechnology, Heidelberg, Germany) was added to the medium from day 7 of culture.
Iron proteins and iron content analysis
Ferritin quantification was performed by ELISA as described previously.
1,2 Electromobility shift assay was performed as described by
Campanella et al. 3 Protein concentration was evaluated by the bicinchoninic acid method (Pierce, Pero, Italy). Cellular 
